News Sentiment

PASG sentiment intelligence

Passage Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.57 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

72/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.4% over one week, -21.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 72/100 classification
One-week reaction -2.4% Price reacting lower
Trend fit Trend inactive -21.3% over four weeks
Fair value -65.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 28
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Stock Titan 8
Market source 6
AD HOC NEWS 2
The Business Journals 2
Moomoo 2
MT Newswires 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Deals and strategy 17
Market update 16
Earnings 13
Regulatory and legal 2
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
AD HOC NEWS Direct company coverage

Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline

Passage Bio Inc. (PASG) is a Nasdaq-listed, clinical-stage genetic medicines company focused on developing gene therapies for rare, monogenic central nervous system disorders. The company leverages an adeno-associated virus-based gene therapy platform and strong academic connecti

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 12:10
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential

Passage Bio Inc. is a clinical-stage genetic medicines company developing gene therapies for rare neurological disorders. The company's strategy involves using adeno-associated virus vectors to correct underlying genetic defects, focusing on clinical progress and regulatory miles

Tone
Positive 63/100
Event
Regulatory and legal
Published
07 Jul 2026 17:44
Source
AD HOC NEWS
TradingView Direct company coverage

Passage Bio, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Passage Bio, Inc.'s financial disclosures and SEC filings, including earnings reports, corporate presentations, and annual meetings, spanning from 2024 to mid-2026. It highlights key events such as M&A announcements, clinical trial pr

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 18:10
Source
TradingView
Ad-hoc-news.de Direct company coverage

Passage Bio explores gene therapy potential as investors weigh long-term prospects

Passage Bio Inc. is a clinical-stage genetic medicine company focused on developing gene therapies for rare neurological disorders, representing a speculative, long-term innovation play for investors. The company's strategy involves advancing candidates through preclinical and ea

Tone
Positive 64/100
Event
Market update
Published
03 Jul 2026 16:10
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal

Lynx1 Capital Management has disclosed a 21% stake in Passage BIO (NASDAQ: PASG) through a Schedule 13D filing, indicating its belief that the stock is undervalued. The filing comes as Passage BIO plans to merge with Remix Therapeutics, with Lynx1 agreeing to participate in a con

Tone
Positive 64/100
Event
Deals and strategy
Published
03 Jul 2026 07:10
Source
Stock Titan
TradingView Direct company coverage

Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake

Lynx1 Capital Management LP has disclosed a 21.0% stake in Passage BIO, Inc., filing a Schedule 13D after its ownership crossed 20%, indicating a more active investment approach. This move is tied to Passage BIO's merger with Remix Therapeutics, with Lynx1 agreeing to participate

Tone
Positive 67/100
Event
Deals and strategy
Published
03 Jul 2026 01:09
Source
TradingView
Finviz Direct company coverage

PASG - Passage Bio Inc Latest SEC Filings

This article provides the latest SEC filings and a comprehensive financial overview for Passage Bio Inc (PASG). It details key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's last close was $4.68, with a m

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 17:10
Source
Finviz
Stock Titan Direct company coverage

Passage Bio (PASG) holder adds 50,055 shares in open-market buy

Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, purchased 50,055 shares of Passage Bio's common stock in an open-market transaction. The shares were bought at a weighted average price of $4.1175, ranging from $3.33 to $4.30 per share. Followi

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Passage Bio, Inc. – NASDAQ:PASG

This article displays the "Price to book forward" metric for Passage Bio, Inc. (NASDAQ: PASG) on the TradingView platform. It presents this financial data point within the context of the company's overall financial information on the site.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 14:10
Source
TradingView
TradingView Direct company coverage

Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG)

This article provides an overview of Passage Bio, Inc. (NASDAQ:PASG) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, volatility, and details from recent earnings reports, n

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG

This article provides financial information for Passage Bio, Inc. (NASDAQ: PASG), specifically detailing its enterprise value to EBIT forward. It is presented on the TradingView platform, which offers various market data and analysis tools for stocks, ETFs, bonds, and cryptocurre

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:09
Source
TradingView
Latham & Watkins LLP Direct company coverage

Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio

Latham & Watkins LLP advised Remix Therapeutics in its definitive merger agreement with Passage Bio. The all-stock transaction will result in the combined company operating as Remix Therapeutics, Inc., trading on Nasdaq under the ticker symbol RMTX. The multidisciplinary legal te

Tone
Positive 67/100
Event
Deals and strategy
Published
26 Jun 2026 06:41
Source
Latham & Watkins LLP
TradingView Direct company coverage

Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG

This article provides the "Price to sales forward" metric for Passage Bio, Inc. (NASDAQ: PASG). It appears to be a financial data point from TradingView, focusing on investment analysis for the biotechnology company. The content primarily lists navigation and data source acknowle

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:41
Source
TradingView
Stock Titan Direct company coverage

Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership

Baselake Partners, LP, along with Baselake Management, LLC and David Paolella, has reported a 7.3% ownership stake in Passage Bio, Inc. (PASG) through a Schedule 13G SEC filing. This amounts to 235,058 shares, based on Passage Bio's 3,207,810 shares outstanding as of May 7, 2026.

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 22:40
Source
Stock Titan
TradingView Direct company coverage

Passage Bio And Remix Therapeutics Announce Merger Agreement

Passage Bio and Remix Therapeutics have announced a merger agreement. This news was reported by Refinitiv via Reuters. The full details of the agreement are available through signing in or creating a free account on the platform.

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing

Passage Bio has signed a definitive merger agreement to acquire Remix Therapeutics in a stock-for-stock deal, valuing Remix at $226 million and Passage Bio at approximately $20 million. The merger includes a concurrent financing of at least $100 million for Remix and will result

Tone
Positive 63/100
Event
Deals and strategy
Published
25 Jun 2026 20:10
Source
TradingView
The Business Journals Direct company coverage

Remix Therapeutics secures $100M and a reverse merger

Remix Therapeutics has announced a successful $100 million private placement financing round, led by Decheng Capital. This funding is part of a reverse merger deal with Passage Bio. The article highlights this significant financial move for Remix Therapeutics.

Tone
Positive 70/100
Event
Deals and strategy
Published
25 Jun 2026 17:40
Source
The Business Journals
BioPharma Dive Direct company coverage

Remix to go public in reverse merger with once high-flying Passage Bio

Remix Therapeutics is set to go public through a reverse merger with Passage Bio, a gene therapy company that has seen its stock price fall significantly. The deal, expected to close in the fourth quarter, will result in Remix investors owning about 93% of the new entity, which w

Tone
Negative 34/100
Event
Deals and strategy
Published
25 Jun 2026 16:40
Source
BioPharma Dive
Moomoo Direct company coverage

Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement

Passage Bio and Remix Therapeutics have announced a definitive merger agreement, under which Remix will merge with a wholly-owned subsidiary of Passage Bio. The combined company will focus on advancing Remix Therapeutics' pipeline of small molecule therapeutics that modulate RNA

Tone
Positive 67/100
Event
Deals and strategy
Published
25 Jun 2026 16:10
Source
Moomoo
TradingView Direct company coverage

PASG Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Passage Bio, Inc. (PASG) stock, drawing on analyst opinions. It includes current stock performance metrics, historical highs and lows, volatility, market capitalization, and details on recent earnings and revenue. The article

Tone
Negative 35/100
Event
Earnings
Published
25 Jun 2026 13:40
Source
TradingView
Stock Titan Direct company coverage

Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M

Passage Bio (PASG) announced a definitive merger agreement with Remix Therapeutics and a concurrent private placement exceeding $100 million. Post-merger, Passage Bio shareholders will own approximately 7% of the combined company, and Remix shareholders will own 93%. The combined

Tone
Negative 39/100
Event
Deals and strategy
Published
25 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise

Passage Bio, Inc. has entered into a definitive merger agreement with Remix Therapeutics, Inc. The deal values Remix at $226 million and Passage Bio at approximately $20 million, with a planned Concurrent Financing of at least $100 million for Remix prior to closing. The combined

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M

Passage Bio (PASG) has entered into a definitive all-stock merger agreement with Remix Therapeutics, Inc., a clinical-stage biotech company. The deal will result in pre-merger Passage Bio shareholders owning about 7% of the combined company and Remix holders about 93%, with Remix

Tone
Neutral 50/100
Event
Deals and strategy
Published
24 Jun 2026 20:10
Source
Stock Titan
Fierce Biotech Direct company coverage

Spurned by the FDA, Passage Bio finds an exit through Remix

Passage Bio, a gene therapy company, has entered an all-stock reverse merger with RNA specialist Remix Therapeutics after facing FDA disapproval for its lead candidate and undergoing a strategic review. The combined company will operate under the Remix name, with Passage Bio shar

Tone
Neutral 50/100
Event
Deals and strategy
Published
24 Jun 2026 17:20
Source
Fierce Biotech
TradingKey Direct company coverage

Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Passage Bio Inc (PASG), detailing analyst ratings, price targets, and EPS expectations. Based on 4 analysts, the current rating is "Hold" with a target price of USD 53.50, suggesting a significant upside. The report highlights past E

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:10
Source
TradingKey